Lonafarnib, Zoledronic Acid, and Pravastatin ( DrugBank: Pravastatin, Zoledronic acid, Lonafarnib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 333 | Hutchinson-Gilford syndrome | 1 |
333. Hutchinson-Gilford syndrome
Clinical trials : 7 / Drugs : 8 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00916747 (ClinicalTrials.gov) | August 2009 | 5/6/2009 | Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies | Progeria | Drug: Lonafarnib, Zoledronic Acid, and Pravastatin | Boston Children's Hospital | Schering-Plough;Merck Sharp & Dohme Corp.;Eiger BioPharmaceuticals | Active, not recruiting | N/A | N/A | All | 85 | Phase 2 | United States |